152
Participants
Start Date
December 31, 2006
Primary Completion Date
December 31, 2014
Study Completion Date
July 31, 2015
rituximab monotherapy
375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
sequential R-CHOP
"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
Div. Universitaria Ematologia e Terapie Cellulari, University of Torino, Torino
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Hematology and Oncology, Augustenburger Platz 1, Berlin
Sahlgrens hospital, Department of Hematology, Gothenburg
Hôpital Pitié-Salpétrière, Department of Hematology, 47-83 Boulevard de l'Hopital, Paris
Zakład Propedeutyki Onkologii, Gdańskiego Uniwersytetu Medycznego, Gdynia
Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, Qld 4102, Brisbane
Catholic University of Leuven, Department of Hematology, Leuven
Charite University, Berlin, Germany
OTHER